Format

Send to

Choose Destination
Vasc Health Risk Manag. 2016 Jun 14;12:251-61. doi: 10.2147/VHRM.S108947. eCollection 2016.

Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.

Author information

1
Private Urology Practice, Bremerhaven, Germany.
2
Institute for Urology and Andrology, Segeberger Kliniken, Norderstedt, Germany; Department of Preventive Medicine, Men's Health Program, Dresden International University, Dresden, Germany; Department of Urology, Gulf Medical University, Ajman, United Arab Emirates.
3
Department for Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA.
4
Department of Urology, Gulf Medical University, Ajman, United Arab Emirates; Global Medical Affairs Andrology, Bayer Pharma AG, Berlin, Germany.
5
Department of Cardiology, Centre for Clinical and Basic Science, San Raffaele-Roma, Rome, Italy.

Abstract

BACKGROUND/OBJECTIVES:

Long-term testosterone therapy (TTh) in men with hypogonadism has been shown to improve all components of the metabolic syndrome. In this study, we investigated the effects of long-term TTh up to 8 years in hypogonadal men with a history of cardiovascular disease (CVD).

PATIENTS AND METHODS:

In two urological clinics observational registries, we identified 77 hypogonadal men receiving TTh who also had a history of CVD. The effects of TTh on anthropometric and metabolic parameters were investigated for a maximum duration of 8 years. Any occurrence of major adverse cardiovascular events was reported. All men received long-acting injections of testosterone undecanoate at 3-monthly intervals.

RESULTS:

In 77 hypogonadal men with a history of CVD who received TTh, we observed a significant weight loss and a decrease in waist circumference and body mass index. Mean weight decreased from 114±13 kg to 91±9 kg, change from baseline: -24±1 kg and -20.2%±0.5%. Waist circumference decreased from 112±8 cm to 99±6 cm, change from baseline: -13±0.3 cm. Body mass index decreased from 37±4 to 29±3, change from baseline: -8±0.2 kg/m(2). Cardio-metabolic parameters such as lipid pattern, glycemic control, blood pressure, heart rate, and pulse pressure all improved significantly and sustainably. No patient suffered a major adverse cardiovascular event during the full observation time.

CONCLUSION:

In men with hypogonadism, TTh appears to be effective in achieving sustained improvements in all cardiometabolic risk factors and may be effective as an add-on measure in the secondary prevention of cardiovascular events in hypogonadal men with a history of CVD.

KEYWORDS:

cardiovascular risk; hypogonadism; long-term testosterone therapy; secondary prevention; testosterone

PMID:
27366080
PMCID:
PMC4913536
DOI:
10.2147/VHRM.S108947
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center